Cytocom Announces Acquisition of ImQuest Life Sciences20200720121029
Cytocom Announces Acquisition of ImQuest Life Sciences
July 20, 20200 comments
WINTER PARK, Fla., July 20, 2020 /PRNewswire/ -- Cytocom, Inc., a private clinical-stage biopharmaceutical company developing novel immune modulating ...
Cytocom, Inc. Announces Successful Completion of Type-B Pre-IND Meeting with FDA Regarding Proposed Phase 2 Clinical Trial of CYTO-201 in COVID-19 Patients20200629114922
Cytocom, Inc. Announces Successful Completion of Type-B Pre-IND Meeting with FDA Regarding Proposed Phase 2 Clinical Trial of CYTO-201 in COVID-19 Patients
June 29, 20200 comments
WINTER PARK, Fla., June 29, 2020 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a private clinical-stage biopharmaceutical company developing novel immune m...
Immune Therapeutics Announces that Equity Partner, Cytocom, Inc., has Filed an Investigational New Drug Application to Conduct a Phase II Clinical Trial Evaluating CYTO-201 Treatment in COVID-19 Patients20200609134518
Immune Therapeutics Announces that Equity Partner, Cytocom, Inc., has Filed an Investigational New Drug Application to Conduct a Phase II Clinical Trial Evaluating CYTO-201 Treatment in COVID-19 Patients
June 9, 20200 comments
Winter Park, Florida–(Newsfile Corp. – June 9, 2020) – Immune Therapeutics, Inc. (OTC Pink: IMUN), announced today that equity partner, Cytocom, Inc.,...
Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-1920200410122646
Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19
April 10, 20200 comments
Immune Therapeutics, Inc. Signs Binding Letter of Intent to Collaborate with Cytocom, Inc. to Develop Lodonal™ and Other Drugs for COVID-19; Other Dru...